{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1&page=10", "query": { "condition": "Phase 1", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 18603, "total_pages": 1861, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T13:59:45.508Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06358430", "title": "Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Minimal Residual Disease" ], "interventions": [ { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "TROP2-CAR-NK Cells", "type": "DRUG" }, { "name": "Rimiducid (AP1903)", "type": "DRUG" }, { "name": "Lymphodepleting Chemotherapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2024-12-02", "completion_date": "2029-01-18", "has_results": false, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-10-23T13:59:45.508Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06358430" }, { "nct_id": "NCT00030628", "title": "Radiosurgery With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Cancer" ], "interventions": [ { "name": "radiation therapy", "type": "RADIATION" }, { "name": "surgery", "type": "PROCEDURE" }, { "name": "WBRT", "type": "RADIATION" } ], "intervention_types": [ "RADIATION", "PROCEDURE" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 480, "start_date": "2001-12", "completion_date": "2014-10", "has_results": false, "last_update_posted_date": "2016-07-07", "last_synced_at": "2026-10-23T13:59:45.508Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Concord, California + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Concord", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00030628" }, { "nct_id": "NCT00262028", "title": "Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prevention of Meningococcal Disease" ], "interventions": [ { "name": "MenACWY-CRM Vaccine", "type": "BIOLOGICAL" }, { "name": "MenACWY-PS Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Vaccines", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "12 Months", "maximum_age": "10 Years", "sex": "ALL", "summary": "12 Months to 10 Years" }, "enrollment_count": 910, "start_date": "2005-04", "completion_date": "2006-11", "has_results": true, "last_update_posted_date": "2016-02-11", "last_synced_at": "2026-10-23T13:59:45.508Z", "location_count": 1, "location_summary": "Oakland, California", "locations": [ { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00262028" }, { "nct_id": "NCT00736528", "title": "A Phase I, Multiple Dose Study of PF-04447943 in Healthy Elderly Volunteers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy", "Elderly" ], "interventions": [ { "name": "PF-04447943", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "65 Years to 85 Years" }, "enrollment_count": 10, "start_date": "2008-08", "completion_date": "2008-09", "has_results": false, "last_update_posted_date": "2009-02-25", "last_synced_at": "2026-10-23T13:59:45.508Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00736528" }, { "nct_id": "NCT03988595", "title": "Exercise Treatment With Standard Therapy for Metastatic Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hormone Receptor Positive Metastatic Breast Cancer" ], "interventions": [ { "name": "Exercise Treatment", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "FEMALE", "summary": "19 Years and older · Female only" }, "enrollment_count": 54, "start_date": "2019-06-12", "completion_date": "2027-08-01", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-10-23T13:59:45.508Z", "location_count": 10, "location_summary": "Indianapolis, Indiana • Baltimore, Maryland • Basking Ridge, New Jersey + 7 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03988595" }, { "nct_id": "NCT03708328", "title": "A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Metastatic Melanoma", "Non-small Cell Lung Cancer (NSCLC)", "Small Cell Lung Cancer (SCLC)", "Esophageal Squamous Cell Carcinoma (ESCC)" ], "interventions": [ { "name": "Lomvastomig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 134, "start_date": "2018-10-15", "completion_date": "2024-07-09", "has_results": true, "last_update_posted_date": "2025-08-20", "last_synced_at": "2026-10-23T13:59:45.508Z", "location_count": 2, "location_summary": "New York, New York • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03708328" }, { "nct_id": "NCT03914300", "title": "Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Differentiated Thyroid Gland Carcinoma", "Follicular Variant Thyroid Gland Papillary Carcinoma", "Poorly Differentiated Thyroid Gland Carcinoma", "Refractory Differentiated Thyroid Gland Carcinoma", "Refractory Thyroid Gland Carcinoma", "Tall Cell Variant Thyroid Gland Papillary Carcinoma", "Thyroid Gland Follicular Carcinoma", "Thyroid Gland Oncocytic Carcinoma", "Thyroid Gland Papillary Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2020-02-10", "completion_date": "2026-12-17", "has_results": true, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-23T13:59:45.508Z", "location_count": 33, "location_summary": "Duarte, California • Los Angeles, California • Newport Beach, California + 25 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03914300" }, { "nct_id": "NCT06741644", "title": "A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "CS2009", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CStone Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 800, "start_date": "2025-02-24", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-23T13:59:45.508Z", "location_count": 2, "location_summary": "Los Angeles, California • Irving, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Irving", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06741644" }, { "nct_id": "NCT07072234", "title": "Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clear Cell Carcinoma", "Phase 1", "Growth Factor" ], "interventions": [ { "name": "Lymphodepleting chemotherapy", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamate", "type": "DRUG" }, { "name": "TGFBR-2 KO CD70 CAR NK", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-09-25", "completion_date": "2030-02-01", "has_results": false, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-10-23T13:59:45.508Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07072234" }, { "nct_id": "NCT01568411", "title": "A Fixed-Sequence, Two-Period, Open-Label Drug-Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD-1211", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "TD-1211", "type": "DRUG" }, { "name": "TD-1211+ itraconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Glycyx Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 20, "start_date": "2012-04", "completion_date": "2012-06", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-23T13:59:45.508Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01568411" } ] }